Interim report
Page 1
Note : This document has been translated from the Japanese original for reference purposes only . In the event of any discrepancy between this translated document and the Japanese original , the original shall prevail . Accounting Standards Consolidated Financial Results for the Three Months Ended June 30 , 2026 FASF MEMBERSHIP August 6 , 2026 ( Under IFRS ) Company name Stock Code URL Representative Ajinomoto Co. , Inc. Stock exchange listing Tokyo Stock Exchange 2802 For inquiries Telephone https://www.ajinomoto.co.jp/company/ Shigeo Nakamura , Representative Executive Officer & President Itoomi Watanabe , Corporate Executive & General Manager , Global Finance Department + 81-3-5250-8111 Scheduled date of starting payment of dividend Preparation of supplementary materials Results briefing Yes Yes ( Yen amounts are rounded down to millions , unless otherwise noted . ) 1. Consolidated Financial Results for the Three Months Ended June 30 , 2026 ( 1 ) Consolidated Operating Results ( Percentages indicate year - on - year changes . ) Sales Business profit Profit before income taxes Profit Three months ended June 30 , 2026 June 30 , 2025 Three months ended June 30 , 2026 Profit attributable to owners of the parent Total comprehensive income Million yen 412,105 364,008 % 13.2 ( 0.4 ) Million yen 60,116 47,236 % 27.3 9.7 Million yen 54,994 14.4 48,072 20.7 % Million yen % 39,312 34,926 12.6 30.4 Basic earnings per share Diluted earnings per share company Million yen 36,452 32,218 % 13.1 34.4 Million yen 48,702 24,664 ( 65.7 ) % 97.5 Yen Yen 38.10 June 30 , 2025 38.11 32.62 32.62 Upon the adoption of IFRS , the Ajinomoto Group has introduced " business profit " as a new profit level that will better enable investors , the Board of Directors , and the Management Committee to grasp the core business results and future outlook of each business while also facilitating continual evaluation of the Group's business portfolio by the Board of Directors and the Management Committee . " Business profit " is defined as sales and share of profit of associates and joint ventures minus cost of sales , selling expenses , research and development expenses , and general and administrative expenses . Business profit does not include other operating income or other operating expenses . 1
Page 2
2 (2) Consolidated Financial Position Total assets Total equity Equity attributable to owners of the parent company Ownership ratio attributable to owners of the parent company As of Million yen Million yen Million yen % June 30, 2026 1,940,438 848,397 774,552 39.9 March 31, 2026 1,812,346 844,275 770,819 42.5 (3) Consolidated Cash Flows Net cash provided by operating activities Net cash used in investing activities Net cash provided by financing activities Cash and cash equivalents at end of period Three months ended Million yen Million yen Million yen Million yen June 30, 2026 18,409 (22,542) 93,639 196,979 June 30, 2025 30,419 (28,983) 34,010 197,921 2. Cash Dividends Annual dividends per share First quarter-end Second quarter- end Third quarter-end Fiscal year-end Total Yen Yen Yen Yen Yen Fiscal year ended March 31,2026 — 24.00 — 24.00 48.00 Fiscal year ending March 31,2027 — Fiscal year ending March 31, 2027 (Forecast) 25.00 — 25.00 50.00 Revisions from the last forecast released: None 3. Forecast for the Fiscal Year Ending March 31, 2027 (Percentages indicate year-on-year changes.) Sales Business profit Profit attributable to owners of the parent company Basic earnings per share Million yen % Million yen % Million yen % Yen Full-year 1,732,000 9.4 202,000 11.5 123,500 (8.3) 129.84 Revisions from the last forecast released: Yes
Page 3
3 Notes (1) Changes in significant subsidiaries during the period: None (2) Changes in accounting policies and accounting estimates (i) Changes in accounting policies as required by IFRS: None (ii) Other changes in accounting policies: None (iii) Changes in accounting estimates: None (3) Number of shares outstanding (ordinary shares) (i) Number of shares outstanding at end of period (including treasury stock) As of June 30, 2026 977,735,616 As of March 31, 2026 977,735,616 (ii) Number of shares in treasury stock at end of period As of June 30, 2026 23,173,875 As of March 31, 2026 19,290,839 (iii) Average number of shares during period Three months ended June 30, 2026 956,451,886 Three months ended June 30, 2025 987,719,450 Note: The number of shares in treasury stock at the end of the period includes the Company’s shares held by the director’s remuneration BIP trust (As of June 30, 2026: 792,000 shares. As of March 31, 2026: 792,000 shares), which was adopted along with the introduction of a Medium-term Stock-based Incentives (MTI) plan for executive officers based on the Company’s medium-term earnings performance for the directors and others. In addition, these Company’s shares are included in the treasury stock which is deducted from the number of shares outstanding at the end of the period when calculating the average number of shares during the period. Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: None Appropriate use of forecasts and other notes Disclaimer regarding forward-looking statements and other information Forward-looking statements, such as business forecasts, included in this document are based on management’s estimates, assumptions, and projections at the time of release. These statements do not promise nor represent a commitment by the Company to achieve these forecasts. Actual operating results may differ significantly due to various factors. For more information regarding earnings forecasts, see page 5, “1. Qualitative Information on the Three-month Consolidated Results, (1) Overview of Operating Results.” Where to obtain supplementary materials Supplementary materials will be posted on the Company’s website on Thursday, August 6, 2026.
Page 4
4 Table of contents 1. Qualitative Information on the Three-month Consolidated Results ...................................................................... 5 (1) Overview of Operating Results ........................................................................................................................ 5 (2) Overview of Financial Position ......................................................................................................................... 9 (3) Overview of Cash Flows .................................................................................................................................. 9 (4) Analysis of Capital Resources and Liquidity .................................................................................................... 9 2. Condensed Consolidated Financial Statements and Notes ............................................................................... 10 (1) Condensed Consolidated Statements of Financial Position ......................................................................... 10 (2) Condensed Consolidated Statements of Income and Condensed Consolidated Statements of Comprehensive Income ................................................................................................................................. 12 (3) Condensed Consolidated Statements of Cash Flows ................................................................................... 14 (4) Notes to Condensed Consolidated Financial Statements ............................................................................. 16 Going Concern Assumption .......................................................................................................................... 16 Significant Changes in Equity Attributable to Owner of the Parent Company .............................................. 16 Segment Information ..................................................................................................................................... 17 Significant Subsequent Events ..................................................................................................................... 19
Page 5
5 1. Qualitative Information on the Three-month Consolidated Results Upon the adoption of IFRS, the Ajinomoto Group has introduced "business profit” as a new profit level that will better enable investors, the Board of Directors, and the Management Committee to grasp the core business results and future outlook of each business while also facilitating continual evaluation of the Group’s business portfolio by the Board of Directors and the Management Committee. “Business profit” is defined as sales and share of profit of associates and joint ventures minus cost of sales, selling expenses, research and development expenses, and general and administrative expenses. Business profit does not include other operating income or other operating expenses. (1) Overview of Operating Results In the three months ended June 30, 2026, the Company’s consolidated sales increased 13.2% year on year, or ¥48.0 billion, to ¥412.1 billion. This was mainly due to increases in sales in the Seasonings and Foods segment and the Healthcare and Others segment. Business profit increased 27.3% year on year, or ¥12.8 billion, to ¥60.1 billion primarily due to the increases in revenue in the Healthcare and Others segment and the Seasonings and Foods segment. Profit attributable to owners of the parent company totaled ¥36.4 billion, up 13.1% year on year, or ¥4.2 billion, primarily as a result of higher business profit. After reevaluating the current business environment, including the impact of escalating tensions in the Middle East, which had not been reflected in the previous forecast, as well as economic conditions, sales trend, raw material costs, and the initiatives being taken by each business division, the Company has revised its forecast for sales, business profit, and profit attributable to owners of the parent company from the forecast previously announced on May 7, 2026. While the sales forecast for the Seasonings and Foods and the Frozen Foods segments remained unchanged, the Company has increased its sales forecast for the Healthcare and Others segment by ¥9.0 billion from the previous forecast, reflecting strong demand for electronic materials used in high- performance circuit boards for AI, server, and network applications. As a result, the total sales forecast was increased by ¥9.0 billion to ¥1,732.0 billion. The progress rate of sales against the revised forecast is 23.8%. The Company has raised its total business profit forecast by ¥5.0 billion from the previous forecast to ¥202.0 billion, due to an upward revision of ¥5.0 billion in business profit in the Healthcare and Others segment reflecting strong sales as described above. Business profit in the Seasonings and Foods segment and the Frozen Foods segment is unchanged from the previous forecast. The progress rate of business profit against the revised forecast is 29.8%. The Company has raised its forecast for profit attributable to owners of the parent company by ¥3.5 billion from the previous forecast to ¥123.5 billion, mainly reflecting the upward revision in business profit. The progress rate of profit attributable to owners of the parent company against the revised forecast is 29.5%. The forecast is based on an exchange rate of ¥150 to US$1. For details on the revised forecast, please also refer to the “Notice of Revision to Full-Year Consolidated Performance Forecast” released today.
Page 6
6 Overview by segment Sales and business profit by segment are summarized below. Versus previous year results (Billions of yen) Sales Business profit FY2026 Q1 YoY change % change FY2026 Q1 YoY change % change Seasonings and Foods 238.7 25.3 11.9% 41.0 4.7 13.0 % Frozen Foods 72.5 3.8 5.6% 2.1 (0.6) (23.2)% Healthcare and Others 97.0 18.0 22.8% 25.1 9.7 63.3 % Other 3.7 0.8 29.8% 1.6 (0.2) (14.0)% Shared companywide expenses — — — (9.9) (0.6) 7.2 % Total 412.1 48.0 13.2% 60.1 12.8 27.3 % Versus the forecast (Billions of yen) Sales Business profit FY2026 Q1 Forecast for the year YTD progress FY2026 Q1 Forecast for the year YTD progress Seasonings and Foods 238.7 998.6 23.9% 41.0 145.9 28.1 % Frozen Foods 72.5 310.6 23.4% 2.1 12.1 17.7 % Healthcare and Others 97.0 406.8 23.8% 25.1 85.0 29.6 % Other 3.7 15.8 23.6% 1.6 5.1 32.4 % Shared companywide expenses — — — (9.9) (46.2) 21.5 % Total 412.1 1,732.0 23.8% 60.1 202.0 29.8 %
Page 7
7 (i) Seasonings and Foods Seasonings and Foods segment sales increased 11.9% year on year, or ¥25.3 billion, to ¥238.7 billion, mainly owing to the effect of currency translation and sales growth. Segment business profit increased 13.0% year on year, or ¥4.7 billion, to ¥41.0 billion, due primarily to the effect of increased revenue. Main factors affecting segment sales Sauce & Seasonings: Overall increase in revenue. Japan: Revenue was level with the previous year. Overseas: Increase in revenue due to currency translation and an increase in sales volume. Quick Nourishment: Overall increase in revenue. Japan: Overall increase in revenue primarily due to increased revenue for coffee products and soups. Overseas: Large increase in revenue due to currency translation and increased sales. Solution & Ingredients: Increase in revenue primarily due to increased sales of restaurant and industrial-use products and currency translation. Main factors affecting segment profits Sauce & Seasonings: Overall large increase in profit. Japan: Increase in profit primarily due to decreased SGA expenses. Overseas: Large increase in profit primarily due to the effect of increased revenue. Quick Nourishment: Overall large increase in profit. Japan: Large increase in profit primarily due to the effect of increased revenue. Overseas: Decrease in profit primarily due to increased strategic expenses, despite increase in revenue. Solution & Ingredients: Overall decrease in profit due to decreased profit for umami seasonings for processed food manufacturers, despite increased profit for restaurant and industrial -use products. (ii) Frozen Foods Frozen Foods segment sales increased 5.6% year on year, or ¥3.8 billion, to ¥72.5 billion, primarily owing to currency translation. Segment business profit decreased 23.2% year on year, or ¥0.6 billion, to ¥2.1 billion. Main factors affecting segment sales Overall increase in revenue primarily due to currency translation. Main factors affecting segment profits Overall large decrease in profit.
Page 8
8 (iii) Healthcare and Others Healthcare and Others segment sales increased 22.8% year on year, or ¥18.0 billion, to ¥97.0 billion, owing to strong sales of electronic materials and other factors. Segment business profit increased 63.3% year on year, or ¥9.7 billion, to ¥25.1 billion, due primarily to the effect of significantly higher revenue in electronic materials. Main factors affecting segment sales Bio-Pharma Services & Ingredients: Increase in revenue due to currency translation and increased sales of amino acids for pharmaceuticals and foods. Functional Materials (electronic materials and others): Large increase in revenue due to strong sales of electronic materials. Others: Overall increase in revenue. Main factors affecting segment profits Bio-Pharma Services & Ingredients: Overall large increase in profit due to increase in profit for both amino acids for pharmaceutical and foods and Bio - Pharma Services (CDMO services). Functional Materials (electronic materials and others): Large increase in profit accompanying large increase in revenue. Others: Overall profit was level with the previous year. (iv) Other In the Other segment, sales increased 29.8% year on year, or ¥0.8 billion, to ¥3.7 billion. Segment business profit decreased 14.0% year on year, or ¥0.2 billion, to ¥1.6 billion.
Page 9
9 (2) Overview of Financial Position As of June 30, 2026, the Company’s consolidated total assets stood at ¥1,940.4 billion, an increase of ¥128.0 billion from ¥1,812.3 billion at the end of the previous fiscal year on March 31, 2026. The main reasons for th e change were increases in cash and cash equivalents and inventories. Total liabilities came to ¥1,092.0 billion, ¥123.9 billion more than the ¥968.0 billion at the end of the previous fiscal year. This was mainly due to an increase in interest bearing debt. Interest bearing debt totaled ¥623.7 billion, an increase of ¥141.0 billion from the end of the previous fiscal year, mainly due to the issuance of commercial papers. Total equity came to ¥848.3 billion, ¥4.1 billion more than the total at the end of the previous fiscal year. Despite a decrease due to the acquisition of treasury stock, this was mainly due to increases in retained earnings and exchange differences on translation of foreign operations resulting from the depreciation of the yen. Equity attributable to owners of the parent company, which is total equity minus non-controlling interests, totaled ¥774.5 billion, and the equity ratio attributable to owners of the parent company was 39.9%. (3) Overview of Cash Flows The overview of cash flows for the three months ended June 30, 2026 is as follows: Net cash provided by operating activities totaled ¥18.4 billion during the three months ended June 30, 2026, compared with ¥30.4 billion during the three months ended June 30, 2025. The main factors included ¥54.9 billion in profit before income taxes and ¥23.4 billion in depreciation and amortization, offset by a ¥28.6 billion increase in inventories, and ¥16.7 billion in income taxes paid. Net cash used in investing activities came to ¥22.5 billion during the three months ended June 30, 2026, compared with ¥28.9 billion during the three months ended June 30, 2025. The main factors included ¥11.7 billion in proceeds from sale and redemption of financial assets offset by ¥33.4 billion in purchase of property, plant and equipment, and intangible assets. Net cash provided by financing activities was ¥93.6 billion during the three months ended June 30, 2026, compared with ¥34.0 billion during the three months ended June 30, 2025. The main factors included ¥140.0 billion in net proceeds from issuance of commercial papers, which offset ¥22.5 billion in dividends paid and ¥19.3 billion in purchase of treasury stock. As a result of the foregoing, cash and cash equivalents as of June 30, 2026 totaled ¥196.9 billion. (4) Analysis of Capital Resources and Liquidity (i) Liquidity During the three months ended June 30, 2026, the Company ensured adequate short -term liquidity on hand through funding methods that mainly consisted of committed credit lines, overdraft facilities, and commercial paper issuance facilities. Moreover, in addition to maintaining an adequate ratio of liquidity on hand, the Company ensured funding security through committed credit lines concluded with its main banks. As of June 30, 2026, the unused amount of committed credit lines was ¥200.0 billion in Japanese yen and US$100 million in foreign currency. Furthermore, the Company provides a loan facility to respond to temporary cash shortages at overseas consolidated subsidiaries with a high possibility of liquidity risks. (ii) Fund Procurement In the three months ended June 30, 2026, the Company raised funds mainly through the issuance of commercial papers in order to fund its operations, taking into consideration the balance between direct and indirect finance from the perspective of funding costs and risk diversification, and the balance between long- term and short-term funding. (iii) Use of Funds During the three months ended June 30, 2026, funds were primarily used to finance business operations.
Page 10
10 2. Condensed Consolidated Financial Statements and Notes (1) Condensed Consolidated Statements of Financial Position (Millions of yen) As of June 30, 2026 As of March 31, 2026 Assets Current assets Cash and cash equivalents 196,979 106,693 Trade and other receivables 202,837 194,221 Other financial assets 38,259 46,670 Inventories 349,747 318,632 Income taxes receivable 10,571 7,656 Others 34,491 30,294 Subtotal 832,888 704,170 Assets of disposal groups classified as held for sale — — Total current assets 832,888 704,170 Non-current assets Property, plant and equipment 650,572 647,381 Intangible assets 91,448 92,231 Goodwill 125,438 124,051 Investments in associates and joint ventures 139,986 138,571 Long-term financial assets 49,176 54,675 Deferred tax assets 12,539 13,844 Others 38,388 37,419 Total non-current assets 1,107,549 1,108,176 Total assets 1,940,438 1,812,346
Page 11
11 (Millions of yen) As of June 30, 2026 As of March 31, 2026 Liabilities Current liabilities Trade and other payables 293,827 303,960 Short-term borrowings 7,069 6,350 Commercial papers 140,000 — Current portion of bonds 29,991 29,988 Current portion of long-term borrowings 4,048 4,095 Other financial liabilities 12,296 11,625 Short-term employee benefits 45,130 51,585 Provisions 1,547 6,362 Income taxes payable 21,312 18,659 Others 20,093 16,435 Subtotal 575,318 449,063 Liabilities of disposal groups classified as held for sale — — Total current liabilities 575,318 449,063 Non-current liabilities Corporate bonds 174,531 174,512 Long-term borrowings 206,280 206,410 Other financial liabilities 64,960 64,810 Long-term employee benefits 33,995 33,943 Provisions 6,872 6,812 Deferred tax liabilities 26,081 28,326 Others 3,999 4,191 Total non-current liabilities 516,722 519,007 Total liabilities 1,092,040 968,070 Equity Common stock 79,863 79,863 Capital surplus 209 — Treasury stock (86,710) (67,337) Retained earnings 604,540 587,856 Other components of equity 176,649 170,436 Other components of equity related to disposal groups classified as held for sale — — Equity attributable to owners of the parent company 774,552 770,819 Non-controlling interests 73,845 73,456 Total equity 848,397 844,275 Total liabilities and equity 1,940,438 1,812,346
Page 12
12 (2) Condensed Consolidated Statements of Income and Condensed Consolidated Statements of Comprehensive Income Condensed Consolidated Statements of Income (Millions of yen) Three months ended June 30, 2026 Three months ended June 30, 2025 Sales 412,105 364,008 Cost of sales (247,475) (224,999) Gross profit 164,630 139,008 Share of profit of associates and joint ventures 2,688 3,128 Selling expenses (56,183) (48,992) Research and development expenses (7,973) (7,345) General and administrative expenses (43,044) (38,562) Business profit 60,116 47,236 Other operating income 1,841 5,293 Other operating expenses (6,062) (3,149) Operating profit 55,895 49,380 Financial income 2,426 2,247 Financial expenses (3,327) (3,555) Profit before income taxes 54,994 48,072 Income taxes (15,681) (13,145) Profit 39,312 34,926 Profit attributable to: Owners of the parent company 36,452 32,218 Non-controlling interests 2,860 2,708 Earnings per share (yen): Basic 38.11 32.62 Diluted 38.10 32.62
Page 13
13 Condensed Consolidated Statements of Comprehensive Income (Millions of yen) Three months ended June 30, 2026 Three months ended June 30, 2025 Profit 39,312 34,926 Other comprehensive income (Net of related tax effects) Items that will not be reclassified to profit or loss: Net gain (loss) on revaluation of financial assets measured at fair value through other comprehensive income (1,221) 1,356 Remeasurements of defined benefit pension plans 659 901 Share of other comprehensive income (loss) of associates and joint ventures (65) 55 Items that may be reclassified subsequently to profit or loss: Cash flow hedges 323 (204) Hedge surplus (48) (92) Exchange differences on translation of foreign operations 9,882 (11,979) Share of other comprehensive loss of associates and joint ventures (139) (299) Other comprehensive income (Net of related tax effects) 9,389 (10,262) Comprehensive income 48,702 24,664 Comprehensive income attributable to: Owners of the parent company 46,000 21,692 Non-controlling interests 2,701 2,971
Page 14
14 (3) Condensed Consolidated Statements of Cash Flows (Millions of yen) Three months ended June 30, 2026 Three months ended June 30, 2025 Cash flows from operating activities Profit before income taxes 54,994 48,072 Depreciation and amortization 23,495 21,031 Impairment loss and gain on reversal of impairment loss 635 321 Increase (decrease) in employee benefits (6,120) (7,311) Increase (decrease) in provisions (4,838) (3,260) Interest and dividend income (1,732) (1,916) Interest expense 2,044 1,801 Share of profit of associates and joint ventures (2,688) (3,128) Loss on sale and retirement of property, plant and equipment, and intangible assets 941 816 Decrease (increase) in trade and other receivables (7,475) (395) Increase (decrease) in trade and other payables 1,501 3,699 Decrease (increase) in inventories (28,633) (18,424) Increase (decrease) in other assets and liabilities 3,056 5,896 Others (1,391) (7,877) Subtotal 33,789 39,325 Interest and dividends received 3,246 3,148 Interest paid (1,895) (1,623) Income taxes paid (16,731) (10,431) Net cash provided by operating activities 18,409 30,419 Cash flows from investing activities Purchase of property, plant and equipment, and intangible assets (33,412) (30,393) Proceeds from sale of property, plant and equipment, and intangible assets 391 117 Purchase of financial assets (1,076) (4,059) Proceeds from sale and redemption of financial assets 11,759 3,422 Proceeds from sale of shares of subsidiaries resulting in change in scope of consolidation — 1,995 Others (204) (66) Net cash used in investing activities (22,542) (28,983)
Page 15
15 (Millions of yen) Three months ended June 30, 2026 Three months ended June 30, 2025 Cash flows from financing activities Net change in short-term borrowings 582 2,100 Net change in commercial papers 140,000 110,000 Repayments of long-term borrowings (231) (7,835) Dividends paid (22,537) (18,811) Dividends paid to non-controlling interests (2,504) (2,588) Purchase of treasury stock (19,373) (46,619) Repayments of lease liabilities (2,296) (2,255) Others — 19 Net cash provided by financing activities 93,639 34,010 Effect of currency rate changes on cash and cash equivalents 779 (2,300) Net change in cash and cash equivalents 90,285 33,145 Cash and cash equivalents at beginning of period 106,693 164,776 Cash and cash equivalents at end of period 196,979 197,921
Page 16
16 (4) Notes to Condensed Consolidated Financial Statements Going Concern Assumption Not applicable Significant Changes in Equity Attributable to Owner of the Parent Company Not applicable
Page 17
17 Segment Information (1) Overview of reportable segments The Group’s reportable segments are categorized primarily by product lines. There are three reportable segments: Seasonings and Foods, Frozen Foods, and Healthcare and Others. Each reportable segment is a component of the Group for which separate financial information is available and evaluated regularly by the Management Committee in determining the allocation of management resources and in assessing performance. The product categories belonging to each reportable segment are as follows: Reportable Segments Details Main Products Seasonings & Foods Sauce & Seasonings Umami seasoning AJI-NO-MOTO®, HON-DASHI®, Cook Do®, Ajinomoto KK Consommé, Pure Select® Mayonnaise, Ros Dee® (flavor seasoning), Masako® (flavor seasoning), Aji-ngon® (flavor seasoning), Sazón® (flavor seasoning), Sajiku® (menu-specific seasoning), CRISPY FRY® (menu-specific seasoning), etc. Quick Nourishment Knorr® Cup Soup, YumYum® (instant noodles), Birdy® (coffee beverage), Birdy® 3in1 (powdered drink), Blendy® brand products (CAFÉ LATORY®, stick coffee, etc.), MAXIM® brand products, Chotto Zeitakuna Kohiten® brand products, various gift sets, office supplies (coffee vending machines, tea servers), etc. Solution & Ingredients Umami seasoning AJI-NO-MOTO® for foodservice and processed food manufacturers in Japan, Seasonings and processed foods for foodservice, Seasonings for processed foods (savory seasonings, enzyme ACTIVA®), Delicatessen products, Bakery products, Nucleotides, Sweeteners (aspartame for industrial use, etc.), and others Frozen Foods Frozen Foods Chinese dumplings (Gyoza, POT STICKERS, etc.), Cooked rice (THE CHA-HAN, CHICKEN FRIED RICE, etc.), Noodles (YAKISOBA, RAMEN, etc.), Sweets (cakes for restaurant and industrial-use, MACARON, etc.), Shumai (THE SHUMAI, Ebi shumai (shrimp dumpling), etc.), Processed chicken (Yawaraka Wakadori Kara-Age (fried chicken), THE KARAAGE, etc.), and others Healthcare & Others Amino Acids for Pharmaceuticals & Foods Amino Acids for Pharmaceuticals and Foods, culture media Bio-Pharma Services (CDMO services) Contract development and manufacturing services of pharmaceutical intermediates and active ingredients and others Functional Materials (electronic materials and others) Electronic materials (interlayer insulating material for semiconductor packages ABF™, etc.), Functional materials (adhesive PLENSET®, magnetic materials AFTINNOVA® Magnetic Film, etc.), activated carbon, release paper, etc. Others Feed-use amino acids, Sports nutrition (Supplement (amino VITAL®), etc.), Personal care ingredients (an amino acid-based surfactant (Amisoft®), and amino acid-based oil and powder for use in makeup (Eldew® and Amihope®, respectively), etc.), Medical foods, Crop services, etc.
Page 18
18 (2) Sales and profits by segment The Group’s sales and profits by reportable segment are as follows: Inter-segment sales and transfers are primarily based on transaction prices with third parties. 1. Other includes the tie-up and other service-related businesses. 2. Adjustments of segment profit or loss are shared companywide expenses, which are expenses not attributable to specific reportable segments. Shared companywide expenses mainly relate to the parent company’s administrative divisions. 1. Other includes the tie-up and other service-related businesses. 2. Adjustments of segment profit or loss are shared companywide expenses, which are expenses not attributable to specific reportable segments. Shared companywide expenses mainly relate to the parent company’s administrative divisions. Three months ended June 30, 2026 (April 1, 2026 to June 30, 2026) (Millions of yen) Reportable Segments Other1 Total sales Adjustments2 As included in consolidated statements of income Seasonings and Foods Frozen Foods Healthcare and Others Sales Sales to third parties 238,744 72,591 97,032 3,737 412,105 — 412,105 Inter-segment sales and transfers 2,653 186 1,221 7,248 11,310 (11,310) — Total sales 241,398 72,778 98,254 10,986 423,416 (11,310) 412,105 Share of profit of associates and joint ventures 1,062 — (47) 1,673 2,688 — 2,688 Segment profit or loss (Business profit or loss) 41,044 2,160 25,171 1,656 70,032 (9,915) 60,116 Other operating income 1,841 Other operating expenses (6,062) Operating profit 55,895 Financial income 2,426 Financial expenses (3,327) Profit before income taxes 54,994 Three months ended June 30, 2025 (April 1, 2025 to June 30, 2025) (Millions of yen) Reportable Segments Other1 Total sales Adjustments2 As included in consolidated statements of income Seasonings and Foods Frozen Foods Healthcare and Others Sales Sales to third parties 213,387 68,752 78,989 2,878 364,008 — 364,008 Inter-segment sales and transfers 2,097 126 1,434 6,759 10,418 (10,418) — Total sales 215,485 68,879 80,424 9,637 374,427 (10,418) 364,008 Share of profit of associates and joint ventures 1,161 — (35) 2,002 3,128 — 3,128 Segment profit or loss (Business profit or loss) 36,332 2,812 15,412 1,926 56,484 (9,247) 47,236 Other operating income 5,293 Other operating expenses (3,149) Operating profit 49,380 Financial income 2,247 Financial expenses (3,555) Profit before income taxes 48,072
Page 19
19 Significant Subsequent Events Not applicable